A versatile system for rapid multiplex genome-edited CAR T cell generation

The therapeutic potential of CRISPR system has already been demonstrated in many instances and begun to overlap with the rapidly expanding field of cancer immunotherapy, especially on the production of genetically modified T cell receptor or chimeric antigen receptor (CAR) T cells. Efficient genomic disruption of multiple gene loci to generate universal donor cells, as well as potent effector T cells resistant to multiple inhibitory pathways such as PD-1 and CTLA4 is an attractive strategy for cell therapy. In this study, we accomplished rapid and efficient multiplex genomic editing, and re-directing T cells with antigen specific CAR via a one-shot CRISPR protocol by incorporation of multiple gRNAs in a CAR lentiviral vector. High efficient double knockout of endogenous TCR and HLA class I could be easily achieved to generate allogeneic universal CAR T cells. We also generated Fas-resistant universal CAR T cells by triple gene disruption. Simultaneous gene editing of four gene loci using the one-shot CRISPR protocol to generate allogeneic universal T cells deficient of both PD1 and CTLA-4 was also attempted.

[1]  C. Weaver,et al.  Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[3]  David Bryder,et al.  Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. , 2014, Cell stem cell.

[4]  M. Smyth,et al.  Prospects for TIM3-Targeted Antitumor Immunotherapy. , 2011, Cancer research.

[5]  Di Zhang,et al.  CCR5 Gene Disruption via Lentiviral Vectors Expressing Cas9 and Single Guided RNA Renders Cells Resistant to HIV-1 Infection , 2014, PloS one.

[6]  Jennifer A. Doudna,et al.  Sequence- and Structure-Specific RNA Processing by a CRISPR Endonuclease , 2010, Science.

[7]  S. Maher,et al.  Activation‐induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack , 2002, Immunology and cell biology.

[8]  Lei Zhang,et al.  Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.

[9]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[10]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[11]  R. Shattock,et al.  Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. , 2015, The Journal of general virology.

[12]  D. Kemeny,et al.  Activation‐induced cell death of human T‐cell subsets is mediated by Fas and granzyme B but is independent of TNF‐α , 2001, Journal of leukocyte biology.

[13]  C. Bachert,et al.  Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma , 2015, Oncoimmunology.

[14]  Carl H. June,et al.  Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition , 2016, Clinical Cancer Research.

[15]  Joana A. Vidigal,et al.  Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries , 2015, Nature Communications.

[16]  M. Guo,et al.  Role of the Fas/Fas ligand pathway in apoptotic cell death induced by the human T cell lymphotropic virus type I Tax transactivator. , 1997, The Journal of general virology.

[17]  Jenna M. Sullivan,et al.  TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer , 2013, Oncoimmunology.

[18]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[19]  M. Smyth,et al.  Microenvironment and Immunology Anti-TIM 3 Antibody Promotes T Cell IFN-g – Mediated Antitumor Immunity and Suppresses Established Tumors , 2011 .

[20]  K. Ihara,et al.  PD1 as a common candidate susceptibility gene of subacute sclerosing panencephalitis , 2010, Human Genetics.

[21]  David A. Scott,et al.  Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.

[22]  Jennifer A. Doudna,et al.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins , 2015, Proceedings of the National Academy of Sciences.

[23]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[24]  K. Odunsi,et al.  LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model , 2015, Oncotarget.

[25]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[26]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[27]  P. Waring,et al.  Cell death induced by the Fas/Fas ligand pathway and its role in pathology , 1999, Immunology and cell biology.

[28]  Luigi Naldini,et al.  A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. , 2012, Blood.

[29]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[30]  K. Kelly-Spratt,et al.  Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD , 2015, Cancer Immunology Research.

[31]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[32]  Aymeric Duclert,et al.  Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. , 2015, Cancer research.

[33]  A. Martini,et al.  Activation-induced cell death and Fas-induced apoptosis in patients with systemic or pauciarticular juvenile idiopathic arthritis. , 2001, Clinical and experimental rheumatology.

[34]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[35]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.